The Outcome of Accidental Bacille Calmette-Guérin Overdose During Routine Neonatal Immunization
Leonore Greybe1, July L Morrison, H Simon Schaaf
1From the Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Insights
Newborn infants accidentally received a high dose of the tuberculosis vaccine, Bacille Calmette-Guérin. Subsequent treatment with isoniazid and rifampicin showed only mild local adverse reactions, with all infants recovering fully within six months.
Area of Science:
- Pediatric infectious diseases
- Immunization safety
- Tuberculosis prevention
Background:
- Bacille Calmette-Guérin (BCG) is a widely used vaccine for tuberculosis prevention.
- Accidental high-dose administration of vaccines can pose safety concerns.
Purpose of the Study:
- To evaluate the outcomes and adverse reactions in newborn infants who received an overdose of Bacille Calmette-Guérin vaccine.
- To assess the safety and efficacy of subsequent high-dose isoniazid and rifampicin preventive therapy.
Main Methods:
- Retrospective study design.
- Inclusion of 14 newborn infants who received 62.5 times the recommended BCG dose.
- Administration of high-dose isoniazid and rifampicin (20 mg/kg/d each) for 6 months.
Main Results:
- All infants experienced mild local adverse reactions.
- One-third of adverse reactions resolved within 16 weeks.
- All adverse reactions resolved by 6 months.
Conclusions:
- High-dose Bacille Calmette-Guérin administration in newborns resulted in mild, transient local adverse reactions.
- High-dose isoniazid and rifampicin preventive therapy was well-tolerated in this cohort.
- The safety profile suggests that prompt medical intervention can mitigate risks associated with BCG overdose.
Abstract:
We report a retrospective study on outcome of 14 newborn infants who received 62.5 times the recommended dose of Bacille Calmette-Guérin for immunization. All infants then received high-dose isoniazid and rifampicin (20 mg/kg/d each) as preventive therapy for 6 months. All had mild local adverse reactions, a third resolving within 16 weeks and all by 6 months.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccinations
Prevention of Further Absorption of Poison
